NASDAQ: GLSI
Greenwich Lifesciences Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their GLSI stock forecasts and price targets.

Forecast return on equity

Is GLSI forecast to generate an efficient return?

Company
-1,419.75%
Industry
113.11%
Market
268.46%
GLSI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GLSI forecast to generate an efficient return on assets?

Company
-653.97%
Industry
32.43%
GLSI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GLSI earnings per share forecast

What is GLSI's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.12
Avg 2 year Forecast
-$1.51
Avg 3 year Forecast
-$1.50

GLSI revenue forecast

What is GLSI's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$8.9M

GLSI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLSI$9.21N/AN/A
INO$2.35$6.50+176.60%Buy
CLNN$12.50$33.75+170.00%Strong Buy
AGEN$3.97$14.50+265.24%Buy
SEER$2.21N/AN/A

Greenwich Lifesciences Stock Forecast FAQ

What is GLSI's earnings growth forecast for 2025-2027?

(NASDAQ: GLSI) Greenwich Lifesciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 56.18%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.16%.

Greenwich Lifesciences's earnings in 2025 is -$17,992,572.On average, 4 Wall Street analysts forecast GLSI's earnings for 2025 to be -$15,223,634, with the lowest GLSI earnings forecast at -$16,697,065, and the highest GLSI earnings forecast at -$13,453,064. On average, 3 Wall Street analysts forecast GLSI's earnings for 2026 to be -$20,576,236, with the lowest GLSI earnings forecast at -$19,769,325, and the highest GLSI earnings forecast at -$21,181,419.

In 2027, GLSI is forecast to generate -$20,437,207 in earnings, with the lowest earnings forecast at -$19,635,748 and the highest earnings forecast at -$21,038,302.

If you're new to stock investing, here's how to buy Greenwich Lifesciences stock.

What is GLSI's revenue growth forecast for 2025-2027?

(NASDAQ: GLSI) Greenwich Lifesciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 288.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.85%.

Greenwich Lifesciences's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast GLSI's revenue for 2025 to be $0, with the lowest GLSI revenue forecast at $0, and the highest GLSI revenue forecast at $0. On average, 3 Wall Street analysts forecast GLSI's revenue for 2026 to be $0, with the lowest GLSI revenue forecast at $0, and the highest GLSI revenue forecast at $0.

In 2027, GLSI is forecast to generate $121,650,044 in revenue, with the lowest revenue forecast at $116,879,454 and the highest revenue forecast at $125,234,801.

What is GLSI's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: GLSI) forecast ROA is -653.97%, which is lower than the forecast US Biotechnology industry average of 32.43%.

What is GLSI's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: GLSI) Greenwich Lifesciences's current Earnings Per Share (EPS) is -$1.36. On average, analysts forecast that GLSI's EPS will be -$1.12 for 2025, with the lowest EPS forecast at -$1.23, and the highest EPS forecast at -$0.99. On average, analysts forecast that GLSI's EPS will be -$1.51 for 2026, with the lowest EPS forecast at -$1.45, and the highest EPS forecast at -$1.55. In 2027, GLSI's EPS is forecast to hit -$1.50 (min: -$1.44, max: -$1.54).

What is GLSI's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: GLSI) forecast ROE is -1,419.75%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.